Methodological Vulnerabilities in the SEA-AD snRNA-seq Dataset

The SEA-AD dataset presents what I characterize as a paradox of scale—the very features that render it impressive (half a million nuclei, multi-regional sampling, standardized protocols) simultaneously obscure critical statistical and biological limitations that undermine its utility for making causal disease inferences. While the dataset provides unprecedented cellular resolution, its foundational architecture rests upon several assumptions that remain insufficiently validated. First, the cross-sectional postmortem design introduces profound temporal ambiguity. The dataset captures a static “snapshot” of cellular states at death, yet Alzheimer’s disease unfolds over decades. A cell expressing disease-associated markers in postmortem tissue cannot be definitively distinguished from one that is: (a) responding to terminal hypoxia, (b) reflecting agonal processes, or (c) experiencing postmortem artifact. The paper by Gazestani et al. (PMID: 37774681) acknowledges transient cell states in AD cortex, but distinguishing these from artifactual signatures remains methodologically unresolved. This temporal confounding is not merely a minor nuisance—it fundamentally compromises causal inference about disease progression. Second, the dataset exhibits undisclosed sampling bias in cell type representation. Single-nucleus RNA sequencing (snRNA-seq) systematically excludes certain cell populations based on nuclear envelope integrity and chromatin accessibility. Pyramidal neurons—highly vulnerable in AD—frequently yield lower quality nuclei, leading to systematic underrepresentation of precisely the cells most biologically relevant to disease pathogenesis. The implicit assumption that nucleus capture rates are independent of disease state is biologically implausible; amyloid deposition and tau pathology may alter nuclear morphology, thereby distorting observed cell type frequencies in a disease-dependent manner. Third, the statistical framework for detecting rare cell populations lacks transparency. While 500,000 cells appears massive, the effective sample size for detecting disease-specific microglial subpopulations (e.g., disease-associated microglia or DAM cells) depends on sampling depth, library preparation efficiency, and biological variance across donors. Power calculations for these rare population comparisons are not prominently featured in documentation. The literature (PMID: 34767070) reveals substantial inter-individual variability in glial tr

Debate provenance: derived from debate sess_gap-methodol-20260427-041425-9e73b245 on question: Methodology challenge: dataset ‘Allen Brain SEA-AD Single Cell Dataset’ — evaluate design, statistical methods, and reproducibility.. Consensus signal: domain_expert, skeptic, theorist discussed the mechanism terms DAM, Dataset, Methodological, PMID, Position, RNA, SEA, SEA-AD. Novelty signal: skeptic-discussed-with-qualified-concession.